PubRank

MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery

Clinical Trial ID NCT01098344

PubWeight™ 24.40‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01098344

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The pancreas cancer microenvironment. Clin Cancer Res 2012 4.10
2 Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther 2013 1.96
3 Notch inhibitors for cancer treatment. Pharmacol Ther 2013 1.55
4 Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol 2010 1.40
5 Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 2011 1.36
6 Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res 2011 1.31
7 Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin Cell Dev Biol 2012 1.17
8 Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol 2013 1.05
9 The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Mol Cancer Ther 2012 0.99
10 Current and future systemic treatment options in metastatic pancreatic cancer. J Gastrointest Oncol 2014 0.95
11 Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther 2013 0.95
12 Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol 2015 0.91
13 Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer. Cancer Growth Metastasis 2015 0.90
14 Notch signaling in serous ovarian cancer. J Ovarian Res 2014 0.87
15 New targeted therapies in pancreatic cancer. World J Gastroenterol 2015 0.87
16 Therapeutics formulated to target cancer stem cells: Is it in our future? Cancer Cell Int 2011 0.83
17 Contribution of epithelial-mesenchymal transition to pancreatic cancer progression. Cancers (Basel) 2010 0.82
18 Therapeutic approaches to target cancer stem cells. Cancers (Basel) 2011 0.80
19 Cancer stem cells in glioma: challenges and opportunities. Transl Cancer Res 2013 0.80
20 Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go? World J Gastrointest Oncol 2015 0.78
21 Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies. World J Gastroenterol 2016 0.77
Next 100